Effect of remimazolam on serum inflammatory markers of diabetic patients under general anesthesia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0008909

Enrollment

140

Registered

2023-10-30

Start date

2022-07-05

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Patients in propofol group were induced anesthesia with 2 mg/kg of propofol and maintained with a target-controlled infusion of propofol using the Marsh effect site model and target BIS monitor

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: type 2 diabetic patients scheduled for general surgery

Exclusion criteria

Exclusion criteria: Patients are excluded if they have underlying diseases such as cardiovascular disease, pulmonary disease, renal disease, liver disease, cognitive dysfunction, congenital malformation, or history of hypersensitivity to benzodiazepine drugs other than well-controlled hypertension.

Design outcomes

Primary

Measure	Time frame
Blood Sugar and Inflammation factors	—

Secondary

Measure	Time frame
Insulin, Glucagon	—

Countries

Korea, Republic of

Contacts

Public ContactYOON JI CHOI

Korea University Ansan Hospital

yoonji07@gmail.com+82-31-412-5289

Outcome results